Real-World Observational Study Using US Pharmacy Claims Data to Assess Safety Outcomes and Treatment Patterns in the US Among Migraine Patients Treated with REYVOW (Lasmiditan) Long Term (H8H-MC-B010)

17/04/2023
03/10/2025
EU PAS number:
EUPAS104191
Study
Planned

ENCePP Code of conduct

No
Data sources

Data sources (types)

Administrative healthcare records (e.g., claims)
Use of a Common Data Model (CDM)

CDM mapping

No
Data quality specifications

Check conformance

Unknown

Check completeness

Unknown

Check stability

Unknown

Check logical consistency

Unknown
Data characterisation

Data characterisation conducted

No